TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

FOSAPREPITANT DIMEGLUMINE

FOSAPREPITANT DIMEGLUMINE
Approved 2016-06-09
Jump to: Indications Approvals Trials Competitors Safety Patents
12
Indications
--
Phase 3 Trials
9
Years on Market

Details

Status
Discontinued
First Approved
2016-06-09
Routes
INTRAVENOUS, UNKNOWN
Dosage Forms
POWDER, UNKNOWN

Companies

ACCORD HLTHCARE MSN CHIA TAI TIANQING PRAXGEN ASPIRO CAPLIN Apotex Teva EUGIA PHARMA GENEYORK PHARMS QILU PHARM HAINAN Viatris Lupin BE PHARMS PIRAMAL CRITICAL Dr. Reddy's Baxter SAGENT PHARMS Fresenius Kabi NAVINTA LLC
Active Ingredient: FOSAPREPITANT DIMEGLUMINE

FOSAPREPITANT DIMEGLUMINE Approval History

Loading approval history...

What FOSAPREPITANT DIMEGLUMINE Treats

12 FDA approvals

Originally approved for its first indication in 2016 . Covers 12 distinct patient populations.

  • Other (12)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

FOSAPREPITANT DIMEGLUMINE FDA Label Details

Pro

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: ANDA204025 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.